Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark R. Corkins is active.

Publication


Featured researches published by Mark R. Corkins.


Journal of Parenteral and Enteral Nutrition | 2009

A.S.P.E.N. Enteral Nutrition Practice Recommendations

Robin Bankhead; Joseph I. Boullata; Susan Brantley; Mark R. Corkins; Peggi Guenter; Joseph Krenitsky; Beth Lyman; Norma A. Metheny; Charles Mueller; Sandra T. Robbins; Jacqueline Wessel

Enteral Nutrition Practice Recommendations Task Force: Robin Bankhead, CRNP, MS, CNSN, Chair; Joseph Boullata, PharmD, BCNSP; Susan Brantley, MS, RD, LDN, CNSD; Mark Corkins, MD, CNSP; Peggi Guenter, PhD, RN, CNSN; Joseph Krenitsky, MS, RD; Beth Lyman, RN, MSN; Norma A. Metheny, PhD, RN, FAAN; Charles Mueller, PhD, RD, CNSD; Sandra Robbins, RD, CSP, LD; Jacqueline Wessel, MEd, RD, CSP, CNSD, CLE; and the A.S.P.E.N. Board of Directors.


Clinical Gastroenterology and Hepatology | 2008

Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children

Elizabeth T. Schaefer; Joseph F. Fitzgerald; Jean P. Molleston; Joseph M. Croffie; Marian D. Pfefferkorn; Mark R. Corkins; Joel D. Lim; Steven J. Steiner; Sandeep K. Gupta

BACKGROUND & AIMS Although eosinophilic esophagitis is recognized increasingly, outcome data guiding therapy are limited. We conducted a prospective randomized trial comparing oral prednisone (P) and swallowed fluticasone (F) for histologic and clinical response. METHODS Patients were randomized to receive P or F for 4 weeks, followed by an 8-week weaning protocol. Esophageal histology was evaluated at baseline and after 4 weeks of therapy. Clinical assessments were performed at weeks 0, 4, 12, 18, and 24. RESULTS Eighty patients with eosinophilic esophagitis were enrolled: 40 in the P arm and 40 in the F arm. Histologic improvement was seen in 30 of 32 P and 34 of 36 F patients, with a greater degree of histologic improvement in the P group. All P and 35 of 36 F patients were free of presenting symptom(s) at week 4. Symptom relapse was seen in 45% of patients by week 24. Kaplan-Meier analysis showed no difference between P and F with regard to relapse rate (P = .7399). No significant difference in time to relapse was found between groups (P = .2529). Systemic adverse effects were noted in 40% of the P arm, whereas esophageal candidal overgrowth was seen in 15% of the F arm. CONCLUSIONS Systemic and topical corticosteroids were effective in achieving initial histologic and clinical improvement. P resulted in a greater degree of histologic improvement, without evidence of an associated clinical advantage over F in terms of symptom resolution, relapse rates, or time to relapse. Symptom relapse was common to both groups upon therapy discontinuation, highlighting the need for maintenance treatment protocols.


Journal of Parenteral and Enteral Nutrition | 2013

Defining Pediatric Malnutrition A Paradigm Shift Toward Etiology-Related Definitions

Nilesh M. Mehta; Mark R. Corkins; Beth Lyman; Ainsley Malone; Praveen S. Goday; Liesje Nieman Carney; Jessica Monczka; Steven W. Plogsted; W. Frederick Schwenk

Lack of a uniform definition is responsible for underrecognition of the prevalence of malnutrition and its impact on outcomes in children. A pediatric malnutrition definitions workgroup reviewed existing pediatric age group English-language literature from 1955 to 2011, for relevant references related to 5 domains of the definition of malnutrition that were a priori identified: anthropometric parameters, growth, chronicity of malnutrition, etiology and pathogenesis, and developmental/ functional outcomes. Based on available evidence and an iterative process to arrive at multidisciplinary consensus in the group, these domains were included in the overall construct of a new definition. Pediatric malnutrition (undernutrition) is defined as an imbalance between nutrient requirements and intake that results in cumulative deficits of energy, protein, or micronutrients that may negatively affect growth, development, and other relevant outcomes. A summary of the literature is presented and a new classification scheme is proposed that incorporates chronicity, etiology, mechanisms of nutrient imbalance, severity of malnutrition, and its impact on outcomes. Based on its etiology, malnutrition is either illness related (secondary to 1 or more diseases/injury) or non-illness related, (caused by environmental/behavioral factors), or both. Future research must focus on the relationship between inflammation and illness-related malnutrition. We anticipate that the definition of malnutrition will continue to evolve with improved understanding of the processes that lead to and complicate the treatment of this condition. A uniform definition should permit future research to focus on the impact of pediatric malnutrition on functional outcomes and help solidify the scientific basis for evidence-based nutrition practices.


The Journal of Pediatrics | 1997

Intolerance to protein hydrolysate infant formulas:: An underrecognized cause of gastrointestinal symptoms in infants

Jon A. Vanderhoof; Nancy D. Murray; Stuart S. Kaufman; David R. Mack; Dean L. Antonson; Mark R. Corkins; Deborah Perry; Robert Kruger

The purpose of this study was to determine the effectiveness of an amino acid-based infant formula in infants with continued symptoms suggestive of formula protein intolerance while they were receiving casein hydrolysate formula (CHF). Twenty-eight infants, 22 to 173 days of age, were enrolled; each had received CHF for an average of 40 days (10 to 173 days) and continued to have bloody stools, vomiting, diarrhea, irritability, or failure to gain weight, or a combination of these symptoms. Sigmoidoscopy with rectal biopsy was performed in all infants. The infants then received an amino acid-based infant formula, Neocate, for 2 weeks. After 2 weeks of treatment, 25 of the infants demonstrated resolution of their symptoms and underwent challenge with CHF. Of the 25 who were challenged, eight tolerated the CHF and the remainder had recurrence of their symptoms. The histologic features in these infants varied from eosinophilic infiltration to normal. We conclude that not all infants with apparent formula protein-induced colitis respond to CHF and that these infants may have resolution of their symptoms when fed an amino acid-based infant formula.


Gastrointestinal Endoscopy | 2004

White specks in the esophageal mucosa: an endoscopic manifestation of non-reflux eosinophilic esophagitis in children☆

Joel R. Lim; Sandeep K. Gupta; Joseph M. Croffie; Marian D. Pfefferkorn; Jean P. Molleston; Mark R. Corkins; Mary M. Davis; Philip P Faught; Steven J. Steiner; Joseph F. Fitzgerald

BACKGROUND White specks in the esophageal mucosa have been observed in children with eosinophilic esophagitis. The aim of this study was to determine the relationship between white specks in the esophageal mucosa and allergic (non-reflux) eosinophilic esophagitis. METHODS Endoscopic data, pH probe results, and histopathology reports for children with esophageal endoscopic abnormalities seen during a 17-month period were reviewed. Eosinophilic esophagitis was grouped according to the number of eosinophils per high power field (non-allergic, <15 eosinophils/high power field; allergic, > or =15 eosinophils/high power field). RESULTS Of 1041 endoscopies performed during the study period, 153 revealed evidence of eosinophilic esophagitis. Of these 153, 61 had fewer than 15 eosinophils/high power field and 92 had 15 or more eosinophils/high power field. At 31 of the 153 procedures, white specks were noted in the esophageal mucosa. The sensitivity of white specks in the esophageal mucosa for allergic eosinophilic esophagitis was only 30%, but the specificity was 95%. pH probe testing was performed in 21 patients with white specks and was normal in all. CONCLUSIONS This report describes a new endoscopic finding associated with allergic eosinophilic esophagitis in children. Eosinophilic esophagitis tends to be severe when white specks are present (> or =15 eosinophils/high power field) and is not associated with pathologic gastroesophageal reflux, as demonstrated by pH probe testing.


Journal of Parenteral and Enteral Nutrition | 2014

Malnutrition Diagnoses in Hospitalized Patients United States, 2010

Mark R. Corkins; Peggi Guenter; Rose Ann DiMaria-Ghalili; Gordon L. Jensen; Ainsley Malone; Sarah J. Miller; Vihas Patel; Steve Plogsted; Helaine E. Resnick

Malnutrition is common among hospitalized patients in the United States, and its coded prevalence is increasing. Malnutrition is known to be associated with increased morbidity, mortality and healthcare costs. Although national data indicate that the number of malnutrition diagnoses among hospital discharges has been steadily rising, an in-depth examination of the demographic and clinical characteristics of these patients has not been conducted. We examined data from the 2010 Healthcare Cost and Utilization Project (HCUP), the most recent nationally-representative data describing U.S. hospital discharges. Using ICD-9 codes, we constructed a composite variable indicating a diagnosis of malnutrition. Based on our definition, 3.2% of all U.S. hospital discharges in 2010 had this diagnosis. Relative to patients without a malnutrition diagnosis, those with the diagnosis were older, had longer lengths of stay and incurred higher costs. These patients were more likely to have 27 of 29 comorbidities assessed in HCUP. Finally, discharge to home care was twice as common among malnourished patients, and a discharge of death was more than 5 times as common among patients with a malnutrition diagnosis. Taken together, these nationally representative, cross-sectional data indicate that hospitalized patients discharged with a diagnosis of malnutrition are older and sicker and their inpatient care is more expensive than their counterparts without this diagnosis.


Journal of Pediatric Gastroenterology and Nutrition | 2002

The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: A 7-year study

Bisher Abdullah; Sandeep K. Gupta; Joseph M. Croffie; Marian D. Pfefferkorn; Jean P. Molleston; Mark R. Corkins; Joseph F. Fitzgerald

Objectives To assess the role of esophagogastroduodenoscopy in the evaluation of children with suspected inflammatory bowel disease. Methods All children with inflammatory bowel disease who underwent esophagogastroduodenoscopy during their initial evaluation at our institution during a 7-year period (December 1993 to November 2000) were included in the study. Results The study included 115 patients: 81 with Crohn disease (mean age, 11.34 years; 42 males) and 34 with ulcerative colitis (mean age, 11.79 years; 20 males). Abnormal findings on esophagogastroduodenoscopy were noted in 64% of patients with Crohn disease and 50% of children with ulcerative colitis; histologic abnormalities were found in 81.6% and 70.6% of the patients, respectively. Granulomas were found in the upper gastrointestinal tracts of 23 of 81 patients (28.4%), with the most common site being the gastric mucosa. Nine of these 23 patients had granulomas solely in the upper gastrointestinal tract. Additional unsuspected pathology noted included: candidiasis, hiatal hernia, Helicobacter pylori infection, and giardiasis. Conclusions Endoscopic and histologic abnormalities were found in the upper gastrointestinal tracts of a significant number of children with inflammatory bowel disease. While the mechanism(s) underlying these abnormalities in patients with ulcerative colitis is unclear, the pathology can contribute to the patients clinical condition. Pathology in the upper gastrointestinal tract should not exclude a diagnosis of ulcerative colitis. Granulomas, confirming the diagnosis of Crohn disease, were found in the upper gastrointestinal tracts of 28% of our patients with Crohn disease. In some cases, granulomas were found solely in the upper gastrointestinal tracts. Based on our data, esophagogastroduodenoscopy with biopsy should be performed in all pediatric patients with suspected inflammatory bowel disease.


Pediatrics | 2006

Screening for Celiac Disease in Asymptomatic Children With Down Syndrome: Cost-effectiveness of Preventing Lymphoma

Nancy L. Swigonski; Heather L. Kuhlenschmidt; Marilyn J. Bull; Mark R. Corkins; Stephen M. Downs

BACKGROUND. Studies demonstrate an increased prevalence of celiac disease in persons with Down syndrome, leading some organizations and authors to recommend universal screening of children with Down syndrome. However, many children with Down syndrome are asymptomatic, and the long-term implications of screening are unknown. The complication of celiac disease that leads to mortality in the general population is non-Hodgkins lymphomas. OBJECTIVES. The purpose of this research in asymptomatic children with Down syndrome was to (1) calculate the number needed to screen to prevent a single case of lymphoma and (2) present a cost-effectiveness study of screening. METHODS. We constructed a decision tree using probabilities derived from the published literature for Down syndrome or from the general population where Down syndrome-specific data were not available. Celiac disease was determined by serologic screening and confirmation with intestinal biopsy. Sensitivity analysis was used to alter probability estimates affecting the cost of preventing lymphoma. RESULTS. Using our baseline values, the no-screen strategy is dominant; that is, screening not only costs more but also results in fewer quality-adjusted life-years. A screening strategy costs more than


The American Journal of Gastroenterology | 2006

Cysteinyl Leukotriene Levels in Esophageal Mucosal Biopsies of Children with Eosinophilic Inflammation: Are They All the Same?

Sandeep K. Gupta; Marc Peters-Golden; Joseph F. Fitzgerald; Joseph M. Croffie; Marian D. Pfefferkorn; Jean P. Molleston; Mark R. Corkins; Joel R. Lim

500000 per life-year gained. Screening all asymptomatic children with Down syndrome for celiac disease costs almost


Pediatrics | 2012

Organic Foods: Health and Environmental Advantages and Disadvantages

Joel A. Forman; Janet H. Silverstein; Jatinder Bhatia; Steven A. Abrams; Mark R. Corkins; Sarah D. de Ferranti; Neville H. Golden; Jerome A. Paulson; Alice Cantwell Brock-Utne; Heather L. Brumberg; Carla Campbell; Bruce P. Lanphear; Kevin C. Osterhoudt; Megan Sandel; Leonardo Trasande; Robert O. Wright

5 million to prevent a single case of lymphoma. CONCLUSION. These analyses do not support the cost-effectiveness of screening, and more data are needed before recommendations to screen asymptomatic children with Down syndrome for celiac disease can be made.

Collaboration


Dive into the Mark R. Corkins's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sandeep K. Gupta

University of Illinois at Chicago

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard G. MacDonald

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jon A. Vanderhoof

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary M. Davis

Riley Hospital for Children

View shared research outputs
Researchain Logo
Decentralizing Knowledge